CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 345.18 Million CNY | -66.52% |
| 2022 | 1.03 Billion CNY | -76.02% |
| 2021 | 4.29 Billion CNY | 23086.49% |
| 2020 | 18.54 Million CNY | 712.13% |
| 2019 | 2.28 Million CNY | 101.71% |
| 2018 | 1.13 Million CNY | -87.67% |
| 2017 | 9.18 Million CNY | 12.04% |
| 2016 | 8.19 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 171.13 Million CNY | 49.75% |
| 2024 Q1 | 114.28 Million CNY | -32.6% |
| 2023 Q2 | -79.46 Million CNY | -179.03% |
| 2023 Q1 | 100.55 Million CNY | -68.93% |
| 2023 FY | 345.18 Million CNY | -66.52% |
| 2023 Q4 | 169.55 Million CNY | 9.71% |
| 2023 Q3 | 154.54 Million CNY | 294.48% |
| 2022 Q3 | 77.6 Million CNY | -40.5% |
| 2022 Q4 | 323.64 Million CNY | 317.04% |
| 2022 Q1 | 499.35 Million CNY | -58.86% |
| 2022 Q2 | 130.43 Million CNY | -73.88% |
| 2022 FY | 1.03 Billion CNY | -76.02% |
| 2021 Q4 | 1.21 Billion CNY | 18.51% |
| 2021 FY | 4.29 Billion CNY | 23086.49% |
| 2021 Q1 | 466.75 Million CNY | 2328.98% |
| 2021 Q3 | 1.02 Billion CNY | -35.77% |
| 2021 Q2 | 1.59 Billion CNY | 241.65% |
| 2020 Q3 | 1.64 Million CNY | 0.0% |
| 2020 FY | 18.54 Million CNY | 712.13% |
| 2020 Q2 | - CNY | -100.0% |
| 2020 Q1 | 4.02 Million CNY | 1039.45% |
| 2020 Q4 | 19.21 Million CNY | 1068.74% |
| 2019 Q3 | 23.83 Thousand CNY | -98.21% |
| 2019 FY | 2.28 Million CNY | 101.71% |
| 2019 Q2 | 1.33 Million CNY | 133.5% |
| 2019 Q1 | 571.49 Thousand CNY | -86.8% |
| 2019 Q4 | 353.64 Thousand CNY | 1384.03% |
| 2018 Q1 | 283 Thousand CNY | 0.0% |
| 2018 Q3 | 4.32 Million CNY | 1429.33% |
| 2018 Q4 | 4.32 Million CNY | 0.0% |
| 2018 FY | 1.13 Million CNY | -87.67% |
| 2018 Q2 | 283 Thousand CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2017 Q4 | 283 Thousand CNY | 0.0% |
| 2017 FY | 9.18 Million CNY | 12.04% |
| 2017 Q1 | - CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | 8.19 Million CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -33.194% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 96.722% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -484.084% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | 55.965% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 64.092% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 67.22% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 79.773% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | 57.338% |
| PuraPharm Corporation Limited | 406.85 Million HKD | 15.159% |
| SSY Group Limited | 6.46 Billion HKD | 94.659% |
| JBM (Healthcare) Limited | 648.41 Million HKD | 46.765% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 76.483% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.872% |